Serum insulin-like growth factor-i level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: A prospective cohort study

Clinical Cancer Research

Volumn 19, Issue 15, 2013, Pages 4218-4227

  Cho, Eun Ju ^a   Lee, Jeong Hoon ^a   Yoo, Jeong Ju ^a   Choi, Won Mook ^a   Lee, Min Jong ^a   Cho, Yuri ^a   Lee, Dong Hyeon ^a   Lee, Yun Bin ^a   Kwon, Jung Hee ^a   Yu, Su Jong ^a   Lee, Jeong Min ^a   Suh, Kyung Suk ^a   Kim, Kion ^b   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Kim, Chung Yong ^a   Lee, Hyo Suk ^a  

^a Seoul National University   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ADULT; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHILD PUGH SCORE; CONTROLLED STUDY; FEMALE; HUMAN; INJECTION; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERCUTANEOUS ALCOHOL INJECTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; TIME TO RECURRENCE; AGED; BLOOD; DISEASE COURSE; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SERUM; SURVIVAL; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SERUM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881248238     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3443     Document Type: Article

References (34)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.
2. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
3. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31:330-5.
4. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010;28: 4985-95.
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
6. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530-42.
7. Zhao R, Berho M, Nogueras J, Sands D, Weiss E, Wexner S, et al. Positive correlation of insulin-like growth factor-II with proliferating cell index in patients with colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2005;14:1819-22.
8. Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y. Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 2008;49:34-42.
9. Wu YL, Ye J, Zhang S, Zhong J, Xi RP. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004;10:2740-3.
10. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 2002;95:2539-45.
11. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, et al. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology 2011;80:373-81.
12. Shao YY, Huang CC, Lin SD, Hsu CH, Cheng AL. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res 2012;18:3992-7.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
14. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
15. Gunnell D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M, et al. Are diet-prostate cancer associations mediated by the IGF axis? Across-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middleaged men. Br J Cancer 2003;88:1682-6.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
17. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121-6.
18. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129:122-30.
19. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56: 337-44.
20. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005;47:458-72.
21. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9.
22. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-9.
23. Tang SH, Yang DH, Huang W, Zhou HK, Lu XH, Ye G. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 2006;12:4171-7.
24. Lorenzo-Zuniga V, Bartoli R, Masnou H, Montoliu S, Morillas RM, Planas R. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patientswith chronic hepatitis C. Dig Dis Sci 2007;52:3245-50.
25. Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, Herrero JI, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005;43:630-6.
26. Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, et al. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 1997;113:1682-91.
27. Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, Paneda A, et al. Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology 2010;51:912-21.
28. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011;21:35-43.
29. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
30. WuJ, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011;4:30.
31. Bonefeld K, Moller S. Insulin-like growth factor-I and the liver. Liver Int 2011;31:911-9.
32. Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A, et al. Increased IGF-I: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol 2003;59:699-706.
33. Aishima S, Basaki Y, Oda Y, Kuroda Y, Nishihara Y, Taguchi K, et al. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 2006;97: 1182-90.
34. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.